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Lymphocyte signaling cascades responsible for anti-tumor cytotoxicity and inflammatory 
cytokine production must be tightly regulated in order to control an immune response. 
Disruption of these cascades can cause immune suppression as seen in a tumor
microenvironment, and loss of signaling integrity can lead to autoimmunity and other 
forms of host-tissue damage. Therefore, understanding the distinct signaling events that 
exclusively control specific effector functions of “killer” lymphocytes (T and NK cells) is 
critical for understanding disease progression and formulating successful immunother-
apy. Elucidation of divergent signaling pathways involved in receptor-mediated activation 
has provided insights into the independent regulation of cytotoxicity and cytokine pro-
duction in lymphocytes. Specifically, the Fyn signaling axis represents a branch point 
for killer cell effector functions and provides a model for how cytotoxicity and cytokine 
production are differentially regulated. While the Fyn–PI(3)K pathway controls multiple 
functions, including cytotoxicity, cell development, and cytokine production, the Fyn–
ADAP pathway preferentially regulates cytokine production in NK and T cells. In this 
review, we discuss how the structure of Fyn controls its function in lymphocytes and 
the role this plays in mediating two facets of lymphocyte effector function, cytotoxicity 
and production of inflammatory cytokines. This offers a model for using mechanistic and 
structural approaches to understand clinically relevant lymphocyte signaling.
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introduction – Fyn, Pi(3)K, and ADAP
Effector functions of lymphocytes are mediated through signaling cascades that transmit extracel-
lular signals to intracellular response elements. These signaling pathways allow lymphocytes to 
respond to transformed or virally infected cells via cell-mediated cytotoxicity and inflammatory 
cytokine production. The identity of receptor–ligand interactions and downstream intracellular 
proteins responsible for inducing effector functions has been well established in NK and T cells. 
However, the divergent roles of signaling molecules in mediating distinct effector functions remain 
largely uncharacterized. Fyn is a membrane proximal, non-receptor tyrosine kinase responsible for 
initiating signaling cascades downstream of the TCR and multiple NK cell-activating receptors (1). 
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By recruiting multiple downstream effector molecules, Fyn func-
tions as a branch point for signaling divergence.
Fyn is one of nine members (Src, Fyn, Lyn, Lck, Fgr, Yes, Hck, 
Blk, and Frk) of the Src-family of non-receptor tyrosine kinases 
(SFKs) (2). Since the discovery of v-Src and its correspond-
ing cellular protein c-Src, extensive study has characterized 
the pleiotropic nature of this tyrosine kinase family (3). SFKs 
participate in a myriad of cellular functions, including growth, 
differentiation, migration, adhesion, and in lymphocytes, cyto-
toxicity, and cytokine production (4). In T and NK cells, activa-
tion of Fyn induces binding to distinct signaling partners, such as 
PI(3)K-p85α (5, 6) and the lymphocyte-specific scaffold protein 
adhesion and degranulation-promoting adaptor protein (ADAP) 
(7). Recruitment of these substrates through Src-homology (SH) 
domains allows Fyn to initiate and regulate diverse lymphocyte 
effector functions.
Through its ability to recruit and phosphorylate the p85α subu-
nit of PI(3)K, Fyn is able to activate signaling cascades responsible 
for a variety of cellular functions, including cell development, 
cell-mediated cytotoxicity, and production of inflammatory 
cytokines (8). Independent of the PI(3)K pathway, Fyn recruits 
and activates the ADAP signaling axis predominantly responsible 
for cytokine production in lymphocytes. Fyn–ADAP binding 
occurs exclusively in lymphocytes, and activation of this pathway 
is mediated by an interaction between the Fyn SH2 domain and 
the pYDGI motif of ADAP corresponding to residues 625–628 
(9). This interaction induces translocation of ADAP to the mem-
brane and stabilizes the protein. From the membrane, ADAP is 
able to mediate formation of the Carma1-Bcl10-Malt1 (CBM) 
complex critical for NF-κB and AP-1 activation (10–12). These 
transcription factors are critical for inflammatory cytokine and 
chemokine production downstream of the Fyn–ADAP interac-
tion in effector cells (10–12).
Fyn therefore represents a node of signaling divergence for 
two primary outcomes of lymphocyte activation, cytotoxicity 
and inflammatory cytokine production. In this review, we discuss 
how the structure of Fyn allows it to act as a critical regulator of 
divergent signaling pathways and multiple effector functions in 
lymphocytes. We discuss conformational changes necessary for 
substrate recognition, specifically PI(3)K and ADAP, as well as 
control of enzymatic activity. We also discuss how protein struc-
ture allows Fyn to act as the exclusive mediator of the ADAP sign-
aling cascade and resulting inflammatory cytokine production, 
thereby regulating a portion of the systemic immune response.
Domain Structures of Fyn
Src-family of non-receptor tyrosine kinases are pleiotropic in 
nature and multiple family members, including Fyn, are ubiq-
uitously expressed in multiple cell types. This allows them to 
control a variety of cellular functions and highlights the need 
for maintaining signaling integrity both in terms of enzymatic 
activity and substrate specificity (13). Across multiple cell types, 
this regulation is provided by the structure of SFKs which creates 
specificity that controls the substrates of the kinase domain and 
regulates enzymatic activity. In lymphocytes specifically, this 
allows Fyn to act as a branch point in regulating cytotoxicity and 
production of inflammatory cytokines (10–12, 14, 15). The struc-
ture of Fyn provides a potential mechanistic explanation for its 
ability to regulate these diverse effector functions in the context 
of effector-cell signaling. This is critical in activated lymphocytes 
because it enables differential regulation of effector functions 
downstream of a single protein.
The structure of Fyn is conserved across all cell types, and 
in vitro characterization of the protein structure combined with 
in vivo characterization of Fyn function in different cell types pro-
vides a basis for understanding structure-based Fyn regulation in 
lymphocytes. The quaternary structure of Fyn and the consecutive 
arrangement of the SH4, SH3, and SH2 domains control the func-
tion of the kinase domain (SH1) through substrate recognition 
and regulation of enzymatic activity (Figure 1A). The N-terminal 
SH4 domain of Fyn is co-translationally myristoylated on the 
N-terminal Gly2 residue and serves as a membrane targeting and 
anchoring sequence (Figure 1A). The SH4 domain also contains 
a non-conserved region that contributes to the specific functions 
of SFK family members. In the case of Fyn, this unique region 
contains two Cys residues (Cys3 and Cys6) that can be reversibly 
palmitoylated. Studies using fibroblast cell lines show that palmi-
toylation of these residues induces localization to lipid rafts in the 
plasma membrane and contributes to spatial control of signaling 
(16, 17). The SH4 domain of Fyn is followed by consecutive SH3 
and SH2 domains responsible for mediating both intermolecular 
and intramolecular protein interactions (Figure  1A) (18). The 
SH3 domain consists of a β-barrel formed by five anti-parallel 
β-strands (19) and two loops that form a binding pocket for lin-
ear, Pro-rich peptides. The polyproline sequences of interacting 
partners form helical conformations that bind with aromatic side 
chains of the Fyn SH3 domain. The Fyn SH2 domain is character-
ized by a primary binding pocket and a specificity-determining 
region. These two sites interact with a phosphorylated Tyr and 
proximal residues on binding partners (20). The SH2 and SH3 
domains allow Fyn to position substrates adjacent to the bilobal 
tyrosine kinase (SH1) domain at its C-terminus (Figure 1A) (4). 
Both the N- and C-terminal lobes of the SH1 domain contain 
regulatory sequences (the C-Helix in the N-terminal lobe and the 
activation loop in the C-terminal lobe) that control ATP-binding 
and phosphate transfer (21–23). The kinase domain also contains 
a regulatory Tyr (Tyr420) that is auto-phosphorylated upon acti-
vation of enzymatic activity. Collectively, the SH domains and 
quaternary structure of Fyn enable it to act in multiple facets of 
killer cell effector function by providing the substrate specific-
ity and control of enzymatic activity required for regulation of 
divergent signaling.
intrinsic Regulation of Fyn Activation
In  vitro characterization of SFK structures show that the 
function of Fyn is regulated by intramolecular interactions 
between the SH domains that prevent unnecessary activation 
under resting state. Structures of the full-length Fyn protein 
in both the inactive and active conformations remain to be 
elucidated; however, sequence homology and structural data 
of individual domains of Fyn and other SFKs provide a model 
for the intramolecular interactions that regulate Fyn activity in 
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lymphocytes (Figure 1B). X-ray crystallographic structures of 
auto-inhibited Src and Hck reveal that prior to SFK activation, 
the kinase domain is kept in a closed conformation as a result of 
intramolecular binding between a phosphorylated Tyr (Tyr531 in 
Fyn) in the C-terminal regulatory region and the SH2 domain 
(21–23). Despite the presence of high-affinity peptide motifs on 
binding partners of Fyn, this interaction is likely maintained due 
FiGURe 1 | The domain structure and intramolecular interactions of the Fyn kinase. (A) Models of the two primary conformations of the Fyn kinase. The 
domain structure of Fyn consists of four SH domains. The relative positions of the domains are shown in both the inactive (left) and active (right) states. The 
N-terminal SH4/unique domain (blue) lies proximal to the membrane-anchoring myristoylation site. The SH4 domain is followed by the SH3 (gold) and SH2 (green) 
domains responsible for mediating interactions between Fyn and its target substrates. These domains are followed by a linker region that connects the SH2 domain 
to the bilobal SH1/kinase domain (red) responsible for enzymatic activity. The inactive form of the kinase is kept in a closed conformation by intramolecular 
interactions between the SH2 domain and a C-terminal phosphotyrosine as well as by an interaction between the SH3 domain and a polyproline helix in the linker 
region (left). The active conformation is adopted upon disruption of these interactions and opening of the kinase. In the active conformation, the SH2 and SH3 
domains mediate protein–protein interactions, while the kinase domain phosphorylates downstream effectors (right). (B) Ribbon diagrams of the SH3, SH2, and 
SH1 domains show their relative positions in the inactive conformation. Positions are based on the structure of auto-inhibited Src (PDB deposition 2SRC), which has 
an identical domain arrangement. The blue high-lighted area of the SH3domain is the site of interaction with the linker region. The SH2 domain of Fyn (green) 
possesses an Arg residue in the second β-sheet (ArgβB5, Arg176) that is conserved across SFK family members. This Arg residue is the primary site of interaction 
with the phosphotyrosine on target substrates. In the inactive conformation, Arg176 is bound to the C-terminal inhibitory pTyr531 of Fyn. These intramolecular 
interactions place the SH2 and SH3 domains in a position to occlude the kinase domain (red) from substrate binding, thus preventing phosphate transfer. The 
ribbon diagram of the kinase domain is derived from PDB deposition 2DQ7, and the positions of the C-Helix and activation loop (gold) show the structure of the Fyn 
kinase domain complexed with staurosporine. To date, this is the only conformation of the Fyn kinase domain that has been characterized, and it is used here to 
demonstrate the intramolecular interactions that keep Fyn in an inactive state. The SH3 domain ribbon diagram is from PDB deposition 1NYG, and the SH2 ribbon 
diagram is from the PDB deposition 1AOT, and is representative of the SH2 domain bound to a phosphotyrosine-containing peptide.
to the quaternary structure of Fyn creating a high local concen-
tration of the C-terminal inhibitory peptide (24–26). The SH3 
domain of SFKs further stabilizes this conformation by binding 
to a polyproline helix in the linker region between the SH2 and 
kinase domains (Figure 1B) (21–23).
These intramolecular interactions force SFKs into an inac-
tive conformation that results from the quaternary structure 
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of Fyn. In this conformation, the SH3 domains lie proximal 
to the N-terminal lobe of the kinase domain, and the SH2 
domains lie proximal to the C-terminal lobe as a result of 
interacting with the C-terminal phosphotyrosine residue 
(Figure  1B) (21–23, 27). This not only results in partial 
occlusion of the kinase domain due to the close proximity of 
the SH2 and SH3 domains, but it also positions the C-Helix 
and activation loop to prevent ATP and substrate binding 
(21–23). To corroborate these structural data, studies using 
multiple SFKs, including Fyn, show that loss of a functional 
SH2 domain or C-terminal regulatory region leads to aberrant 
kinase activity and cellular transformation (28–30). Together, 
both functional and structural data suggest maintaining the 
correct quaternary structure of Fyn, and the resultant intra-
molecular contacts, is required for the temporal regulation of 
signaling in lymphocytes.
extrinsic Regulation of Fyn Activation by 
Csk and PAG
The quaternary structure of Fyn also provides extrinsic regula-
tion that helps maintain Fyn in an inactive state as evidenced 
by studies in multiple cell types. When Fyn is co-translationally 
myristoylated, the carbon chain of the myristoyl group causes 
translocation of the protein to the plasma membrane (17). Once 
at the membrane, interaction of Fyn with an adaptor protein 
and regulatory kinase forces Fyn into a closed conformation 
(Figure  2A). These events are driven by processive phospho-
rylation, wherein all available sites of a given substrate are 
phosphorylated before the kinase dissociates.
Studies using T cells and mast cells show that at the membrane, 
Fyn first associates with the transmembrane adaptor phospho-
protein-associated with glycosphingolipid-enriched domains/c-
Src kinase (Csk)-binding protein (PAG/CBP) (31–33). This 
interaction is mediated by binding of the SH3 domain of Fyn to 
a Pro-rich region of PAG between residues 131–137 as evidenced 
by in vitro studies using peptides derived from PAG (Figure 2A) 
(34). Along with controlling the protein–protein interaction, 
Solheim et al. used in vitro phosphorylation assays to show that 
this binding event actually increases the enzymatic activity of Fyn 
likely through a switch to a more active conformation (34).
The increased activity of Fyn next results in phosphorylation 
of either Tyr residue Tyr163 or Tyr181 of PAG, which initiates 
binding of the SH2 domain of Fyn (31–33). The resultant 
SH2–phosphotyrosine interaction then leads to processive 
phosphorylation of multiple Tyr residues, including Tyr317of PAG 
necessary for recruitment of the regulatory protein c-Src kinase 
(Csk) (Figure  2A) (33). Association of this kinase with PAG 
allows Csk to phosphorylate the C-terminal inhibitory tyrosine 
of Fyn. Finally, dissociation of Fyn from PAG then induces the 
inactive conformation of Fyn (Figure  2A) (33). This pathway 
demonstrates how protein structure allows for crosstalk between 
different domains and extrinsic control of kinase activity. Taken 
together, these data demonstrate how the quaternary structure 
creates an effective off switch for Fyn activity through extrinsic 
regulation. In lymphocytes, this allows Fyn to maintain an inac-
tive conformation prior to receptor-mediated activation.
Fyn Structure in Activation
The precise mechanism of Fyn activation in lymphocytes is yet 
to be fully characterized; however, several studies suggest that 
disruption of intramolecular interactions triggers Fyn to adopt 
an open conformation. Specifically, Fyn activity has been shown 
to increase following dephosphorylation of C-terminal inhibi-
tory Tyr531 as well as substrate recruitment to the SH3 domain 
(Figure  2B). To date, the primary phosphatase implicated in 
Fyn activation is the transmembrane protein CD45. Murine NK 
cells from CD45-deficient mice show that cytokine production 
is reduced downstream of Ly49D, CD16, and NKG2D receptors 
following activation (35). Several studies using T and NK cells 
also suggest that CD45-mediated dephosphorylation leads to Fyn 
activation. Both murine and human T and NK cells deficient in 
CD45 show hyper-phosphorylation of Tyr531 of Fyn and impaired 
effector functions following receptor-mediated activation 
(35–39). Additionally, hyper-phosphorylation of Fyn prevents 
activation of PLC-γ1 and calcium flux downstream of CD3- and 
CD28-mediated stimulation (40, 41). These data suggest that 
CD45-mediated dephosphorylation is obligatory for Fyn activa-
tion in lymphocytes (42). In  vitro enzyme kinetics assays also 
show that Fyn activation can be achieved through interaction of 
substrates with the SH3 domain (43, 44). Fyn-substrate binding 
results in displacement of the SH3 domain from the linker region 
thereby disrupting intramolecular interactions that keep Fyn in 
an inactive state (44–47). While the complete open structure of 
Fyn has not been elucidated, crystal structures of other SFKs sug-
gest that disruption of these intramolecular interactions displaces 
the SH2 and SH3 domains from the kinase domain (Figure 2B) 
(48). These conformational changes eliminate steric hindrance 
and induce the active state of the Fyn kinase domain.
Crystal structures of Src and Lck show that movement of the 
SH3 and SH2 domains away from the kinase domain alters the 
helical conformation of the activation loop in the C-terminal lobe 
(Figure 1B) of the kinase domain (45–47). This allows for auto-
phosphorylation of an activating Tyr420 in the kinase domain of Fyn. 
This creates an electrostatic interaction that moves the C-Helix of 
the N-terminal lobe (Figure 1B) into an active position where it is 
able to help place ATP for phosphate transfer (45–47). Despite the 
fact that the specific mechanism of Fyn activation in lymphocytes 
has not been characterized, these structural and functional data 
allow us to propose a model whereby Fyn undergoes a confor-
mational switch due to CD45-mediated dephosphorylation and 
binding of PI(3)K-p85α to the SH3 domain. This results in disrup-
tion of intramolecular contacts, converting the kinase domain to 
an active conformation while opening the SH2 and SH3 domains 
to mediate substrate recruitment. These domains give Fyn the 
ability to recruit and phosphorylate distinct downstream proteins 
thereby initiating divergent signaling pathways.
Fyn Recruits Distinct Signaling Partners to 
Regulate Multiple Cellular Functions
The SH3 domain of Fyn is able to bind the PI(3)K-p85α subunit 
and, through phosphorylation, initiate PI(3)K activity (Figure 3). 
Structural data show that a Pro-rich region corresponding to 
FiGURe 2 | Models for inhibition and activation of Fyn. (A) Fyn regulation is reliant on phosphorylation of an inhibitory tyrosine, Tyr531, in the C-terminal 
regulatory region. This is initiated by binding of the SH3 domain of open Fyn to PAG/CBP (gray) (left). This leads to subsequent phosphorylation of tyrosine residues 
on PAG/CBP, and these tyrosine residues bind the SH2 domains of both Fyn and Csk (pink) (center). Csk then phosphorylates the C-terminal inhibitory Tyr531, which 
leads to intramolecular binding of the Fyn SH2 domain and disrupts the interaction of Fyn with PAG/CBP. Fyn is then released from PAG/CBP and remains anchored 
in the membrane as an inactive kinase molecule (right). (B) Fyn is locked in the inactive conformation until cellular activation leads to disruption of intramolecular 
binding. Stimulation through NKG2D leads to activation of the CD45 phosphatase (left). CD45 then removes the phosphate from the C-terminal inhibitory tyrosine 
and disrupts the intramolecular interactions responsible for keeping Fyn in a closed conformation. These interactions are also disrupted upon binding of substrates, 
such as PI(3)K-p85α, to the Fyn SH3 domain. This prevents the SH3 domain from binding to the linker region. Loss of these intramolecular interactions causes Fyn 
to adopt a more open conformation where the SH2 and SH3 domains are able to mediate substrate recruitment, while the kinase domain mediates enzymatic 
activity (right).
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residues 91–104 of PI(3)K-p85α is able to adopt a helical con-
formation and bind the SH3 domain of Fyn (19). This binding 
leads to phosphorylation and activation of PI(3)K-p85α (49). 
These interactions occur downstream of receptor-mediated acti-
vation and are critical for lymphocyte effector function (50–52). 
Studies with PI(3)K-p85α-deficient murine NK cells show loss of 
cytokine production and anti-tumor cytotoxicity (53). In addi-
tion to these functional defects, loss of PI(3)K-p85α also impairs 
lineage commitment and terminal maturation (53). These data 
demonstrate the ability of Fyn to activate multiple lymphocyte 
effector functions through activation of PI(3)K signaling.
The quaternary structure of Fyn also allows it to activate a 
divergent signaling cascade primarily responsible for cytokine 
production in lymphocytes. Recent work has elucidated the 
role of the Fyn–ADAP axis in mediating inflammatory cytokine 
production in activated NK and T cells (10–12, 14). A unique 
pYDGI motif corresponding to residues 625–628 of ADAP 
facilitates its binding to the SH2 domain of Fyn (Figure 3). This 
stabilizes ADAP and allows it to bind the C-terminal region of 
Carma1, leading to CBM signalosome formation, NF-κB translo-
cation, and cytokine production (14). Studies using NKG2D- and 
CD137-mediated activation of NK cells show that these pathways 
FiGURe 3 | Fyn is capable of activating divergent signaling cascades. (A) In the active conformation, the SH2 and SH3 domains bind downstream effectors 
and activate divergent signaling cascades in lymphocytes. The interaction between PI(3)K-p85α and the SH3 domain of Fyn controls multiple aspects of lymphocyte 
effector functions. The SH2 domain of Fyn binds ADAP via the YDGI motif following tyrosine phosphorylation by Fyn. This stabilizes ADAP and initiates a unique set 
of lymphocyte functions, such as cytokine production. (B) ADAP translocation and stabilization leads to CBM complex formation. Carma1 binds to ADAP and 
initiates the recruitment of Bcl10 and Malt1. This leads to TAK1 binding and activation of its kinase activity. TAK1 then activates NF-κB or AP-1. Once activated, 
NF-κB and AP1 translocate to the nucleus where they induce transcription of cytokine and chemokine genes.
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are turned on simultaneously as evidenced by PI(3)K-p85α 
phosphorylation and nuclear translocation of p65 (12). However, 
it remains unclear as to whether a single molecule of Fyn can 
bind both PI(3)K-p85α and ADAP concurrently (Figure 3). The 
fact that these pathways are mediated by different SH domains 
suggests that this type of regulation is possible. Structural analysis 
using multiple Fyn-binding targets may elucidate whether these 
molecules bind simultaneously or in a sequential manner.
The role of the Fyn SH2 domain in initiating the ADAP-
CBM-Tak1 signaling cascade leading to cytokine production 
highlights the importance of the unique structure of the Fyn. 
Lack of ADAP in NK cells impairs only cytokine production but, 
not anti-tumor cytotoxicity (12). However, lack of Fyn alters both 
cytokine production and cytotoxicity, implying that Fyn initiates 
and regulates multiple signaling cascades that, despite being 
regulated by a single protein, are able to function independently. 
The structure of Fyn suggests that this is due to substrate control 
provided by the SH2 and SH3 domain, and in the case of the 
Fyn–ADAP axis, the SH2 domain specifically. To date, over 100 
SH2 domain-containing proteins have been identified (54, 55). 
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Despite this conservation, Fyn remains the sole kinase shown 
to be responsible for activation of ADAP-dependent cytokine 
production. This is due to structural differences creating unique 
binding specificities among protein family members and across 
all SH2 domain-containing proteins. Thus, the SH2 domain 
of Fyn provides an excellent example of how subtle structural 
differences create signaling specificity critical for regulation of 
lymphocyte effector functions.
The Fyn–ADAP interaction: Cytotoxicity 
versus Cytokine Production
All SFKs contain a highly conserved SH2 domain with a prefer-
ence for binding pYEEI phosphopeptide motifs (56). Roughly 
half of the binding energy for this interaction is derived from 
contact between the phosphotyrosine residue and a hydrophilic 
binding pocket located between the N-terminal α-helix and cen-
tral β-sheet of SH2 domains (Figure 4A) (27, 57). The base of this 
pocket is formed by an Arg residue in the β-sheet that mediates 
electrostatic interactions with the phosphotyrosine (Figure 4B). 
This pocket is conserved across SH2 domains and provides the 
basis for SH2–phosphotyrosine interactions (58).
SH2 domains also contain a specificity-determining region 
adjacent to the phosphotyrosine pocket that is required to ensure 
signaling integrity (Figure  4A). Variation in the specificity-
determining region establishes substrate selection among SH2 
domain-containing proteins. In SFKs, this region contains basic 
and polar residues capable of forming hydrogen bonds and 
electrostatic interactions with the +1 Glu residue of the pYEEI 
motif of substrates (56). These additional interactions provide 
an enthalpy-driven increase in affinity, as well as an increase 
in specificity for acidic residues within SFK substrate pYEEI 
motifs (27, 56, 57). The specificity-determining regions of SH2 
domains also contain a hydrophobic pocket formed by two 
C-terminal loops. While the hydrophobic nature of this pocket 
is conserved across SH2 domains, different residue composition 
between protein families leads to different specificities for the 
+3 hydrophobic residue of target pYEEI motifs. In SFKs, a Gly 
residue in the C-terminal loop allows a branched chain Ile to 
fit stably into the hydrophobic pocket (27, 56, 57). Collectively, 
these interactions provide the basis for the specificity of a given 
SH2 domain (27, 57).
Despite the conserved specificity across SFK SH2 domains, 
Fyn is the only SFK that interacts with the pYDGI motif of ADAP 
(15). The structure of Fyn bound to the phosphotyrosine motif of 
ADAP remains to be elucidated. However, crystal structure of Lck 
and Src and NMR solution structures of Fyn bound to a model 
phosphotyrosine motif (pYEEI) provide a potential basis for the 
Fyn SH2 domain interaction with the pYDGI motif of ADAP (20). 
Fyn, Lck, and Src contain an Arg residue within the first α-helix 
(ArgαA2) located at the base of the phosphotyrosine-binding 
pocket. Our analyses using Protein Data Bank (PDB) depositions 
of Fyn, Lck, and Src bound to pYEEI-based peptides show that 
the different positions of this ArgαA2 may influence the confor-
mation of the pYDGI motif in ADAP (Figures 4C,D). As noted 
by Campbell et al., NMR solution structures of Fyn show that the 
side chain of ArgαA2 (Arg134) has a poorly defined position, and 
intramolecular nuclear overhauser effect (NOE) analyses suggest 
that this residue does not contribute directly to phosphotyrosine 
binding (Figure 4C, left). Compared to Lck (Figure 4C, center) 
and Src (Figure 4C, right), ArgαA2 of Fyn is farther away from 
the backbone of the target peptide (6.1 Å in Fyn compared to 3.1 
and 2.7 Å in Src and Lck, respectively) and hydrogen bonding to 
the corresponding main-chain carbonyl of the pYEEI motif does 
not occur (Figure 4C) (20). The structures of both Src and Lck 
show that the side chains of ArgαA2 have well-defined positions. 
The fixed positions of these residues combined with a shorter 
bond distance allows them to interact with phosphate oxygens 
and main-chain carbonyl groups of the pYEEI motif. Contrary 
to what is seen in Fyn, the structures of Src and Lck therefore 
identify ArgαA2 in the phosphotyrosine-binding pocket as a 
critical residue in positioning of the phosphotyrosine motif.
In all three structures, the main-chain carbonyl of a His in 
the fourth β-strand (HisβD4) interacts with backbone amide of 
the Glu residue in the +1 position from the phosphotyrosine 
(Figure 4C) (20, 27, 59). In the case of Src and Lck, the prox-
imity of these interactions (3.0 and 2.8 Å, respectively) locks 
the conformation of the peptide backbone due to high energy 
hydrogen bonding (20, 27, 59). In the case of Fyn, the loss of 
pYEEI-binding to ArgαA2 corresponds to an extended distance 
(3.7 Å) between HisβD4 and the backbone amide of the target 
peptide which results in a lower energy hydrogen bond. Based on 
these structural analyses, we propose that the weaker bond with 
HisβD4 in Fyn allows the pYEEI motif to adopt a more extended 
conformation. This decreases the distance between a Tyr residue 
in the specificity-determining region of the SH2 domain of Fyn 
(TyrβD5) and the +1 glutamate residue of the phosphotyrosine 
motif (Figure  4D, left). Structural data show an increased 
distance between the side chain of the +1 Glu of the pYEEI 
motif and TyrβD5 of Lck and Src as evidenced by the distance 
between the Glu carboxyl group and Tyr hydroxyl group (3.4 Å 
in Fyn compared to 4.5 and 5.3 Å of Lck and Src, respectively) 
(Figure 4D) (20, 27, 59).
Previous characterization of all three structures revealed 
that TyrβD5 binds the +1 glutamate residue of target peptides; 
however, varied bond distances suggest that this contact is con-
trolled by different interactions (20, 27, 59). The proximities of 
the carboxyl group of the +1 Glu to the hydroxyl group of TyrβD5 
suggest that hydrogen bonding may participate in this interaction 
in Fyn but not in Src or Lck (20, 27, 59). In Src and Lck, this 
interaction is instead likely reliant upon hydrophobic interactions 
between the ring group of TyrβD5 of the SH2 domain and the 
side chain carbons of the +1 Glu of the pYEEI motif (20, 27, 59). 
These hydrophobic interactions may necessitate a longer side 
chain with an increased number of carbons in the +1 position 
of phosphotyrosine motifs in order to satisfy the hydrophobic 
interactions required to tightly bind Src and Lck substrates. This 
would prevent binding of peptides with shorter chain amino acids 
substituted in the +1 position, thereby preventing Src and Lck 
from interacting with the pYDGI motif of ADAP. The specificity 
of the Fyn–ADAP interaction may therefore enable lymphocytes 
to regulate proinflammatory cytokine production by limiting the 
amount of activated SFKs that can initiate downstream signaling 
cascades of ADAP.
FiGURe 4 | Specificity of the Fyn–ADAP interaction. (A) Surface and ribbon models show the Fyn SH2 domain bound to a pYEEI peptide motif. Green shading 
on the surface model represents the phosphotyrosine-binding pocket, while red shading represents the specificity-determining region. The ribbon model shows that 
the pYEEI peptide lies orthogonal to the β-sheet of the SH2 domain. This positions the phosphorylated tyrosine in a hydrophilic pocket in between the β-sheet and 
the αA helix. The linear conformation of the peptide allows residues C-terminal to the phosphotyrosine to interact with other regions of the SH2 domain, which 
increases specificity and affinity of the Fyn–substrate interaction. Both the surface and ribbon model are derived from PDB deposition 1AOT. (B) An exploded view of 
the primary binding pocket highlights the interaction between the phosphotyrosine and the conserved ArgβB5 of Fyn. Salt-bridge formation at this site contributes 
roughly 50% of the binding energy required for the SH2 peptide interaction. (C) Comparison of different SFKs bound to pYEEI motifs show varied interactions at the 
phosphotyrosine-binding pocket. Ribbon models of Fyn (left), Lck (center), and Src (right) highlight bond distances between ArgαA2 of the SH2 domain and a 
backbone carbonyl on the target peptide (#1). Bond distances show that ArgαA2 is capable of interacting with the backbone of the pYEEI motif in Src and Lck but 
not in Fyn. Ribbon models also show the distance between the backbone carbonyl of HisβD4 of the SH2 domain and backbone amide of the pYEEI motif (#2). 
These bond distances suggest that the structure of the Fyn SH2 domain places pYEEI motifs in a more extended conformation than that seen in Src or Lck. (D) 
Measurements obtained from PDB depositions show the distance between TyrβD5 of the SH2 domain and the glutamate residue in the +1 position from the 
phosphotyrosine. The shorter distance in Fyn (left) means that hydrogen bonding is possible between TyrβD5 and the +1 glutamate residue of the pYEEI motif, while 
bonding is based primarily on hydrophobic interactions (red dashes) in Lck (center) and Src (right). This may provide an explanation for the ability of Fyn to act as the 
sole kinase responsible for recruitment of ADAP, as less hydrophobic interactions would be possible between the SH2 domain and YDGI motif of ADAP. 
Measurements are based on PDB depositions 1AOT for Fyn, 1LKK for Lck, and 1SPS for Src.
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Conclusion
The Fyn–ADAP axis highlights the importance of structure in 
controlling divergent signaling cascades responsible for unique 
effector functions in lymphocytes. The structure of multiple SFKs, 
including Fyn, reveals the intramolecular interactions between 
the SH2 domain and C-terminal phosphotyrosine critical for 
regulating kinase activity. These structures in turn play an integral 
role in characterizing the conformational changes required to 
activate and inhibit SFKs. This provides mechanistic insight into 
both intrinsic and extrinsic regulation of Fyn. Once activated, the 
intramolecular organization of Fyn’s SH2 and SH3 domains allows 
the protein to recognize and phosphorylate multiple targets that 
control cellular function. Because Fyn is able to target both PI(3)
K and ADAP, it is able to control cytotoxicity and cytokine pro-
duction in NK cells. Data from our lab and others suggest that the 
ability of Fyn exclusively to activate ADAP is a result of structural 
differences between SFKs that allow Fyn to bind the pYDGI motif 
of ADAP. To date, no mechanistic basis for Fyn–ADAP specificity 
has been confirmed, and proving any underlying structural cause 
will likely require solving the structure of the Fyn SH2 domain 
complexed with a pYDGI containing peptide. Solving this struc-
ture has the potential to elucidate the mechanism behind the 
signaling specificity responsible for distinct effector functions in 
lymphocytes, and serve as a model for identifying other divergent 
signaling cascades.
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